We leverage our proprietary kinase switch control inhibitor platform to develop of highly selective, potent small molecule drug candidates that directly inhibit activation of kinases implicated in the growth and spread of cancers. We currently retain global development and commercialization rights to all of the drug candidates in our pipeline.

 Pre-ClinicalPhase 1Phase 1b/2Phase 3Global Rights
Ripretinib*: Broad Spectrum Inhibitor of KIT & PDGFRα
Gastrointestinal Stromal Tumors
 
   Deciphera Logo
     
Systemic Mastocytosis
 
   
     
Other Solid Tumors
(includes Gliomas, NSCLC, & Sarcomas)
 
 

 

   
Rebastinib: Selective Inhibitor of TIE2
Solid Tumors in Combination with paclitaxel
(includes breast, ovarian & endometrial cancers)
 
   Deciphera Logo
     
Solid Tumors in Combination with carboplatin
(includes mesothelioma, ovarian & breast cancers)
 
 

 

   
DCC-3014: Selective Inhibitor of CSF1R
Solid Tumors & Tenosynovial Giant Cell Tumors
 
   Deciphera Logo
     
Additional Programs
Cancer Metabolism
(undisclosed kinase)
 
   Deciphera Logo
     
Immunokinase
(undisclosed kinase)
 
 

 

   

*DCC-2618

Ripretinib, rebastinib and DCC-3014 are investigational new drugs under development and are not approved for marketing by any health authorities.